These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28600503)

  • 1. Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma.
    Zeng S; Yu X; Ma C; Song R; Zhang Z; Zi X; Chen X; Wang Y; Yu Y; Zhao J; Wei R; Sun Y; Xu C
    Sci Rep; 2017 Jun; 7(1):3151. PubMed ID: 28600503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANLN Serves as an Oncogene in Bladder Urothelial Carcinoma via Activating JNK Signaling Pathway.
    Chen S; Gao Y; Chen F; Wang TB
    Urol Int; 2023; 107(3):310-320. PubMed ID: 35504258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
    Zeng S; Liu A; Dai L; Yu X; Zhang Z; Xiong Q; Yang J; Liu F; Xu J; Xue Y; Sun Y; Xu C
    BMC Cancer; 2019 Jun; 19(1):604. PubMed ID: 31216997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
    Magnusson K; Gremel G; Rydén L; Pontén V; Uhlén M; Dimberg A; Jirström K; Pontén F
    BMC Cancer; 2016 Nov; 16(1):904. PubMed ID: 27863473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
    Wang Z; Hu S; Li X; Liu Z; Han D; Wang Y; Wei L; Zhang G; Wang X
    BMC Cancer; 2021 Nov; 21(1):1188. PubMed ID: 34743685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification.
    Liu R; Ma J; Zhang Y; Zhou Z
    Front Immunol; 2024; 15():1449251. PubMed ID: 39430746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.
    Luo HB; Li B; Yuan WG; Xu CR
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening
    Yang T; Chi Z; Liu G; Hong X; Cao S; Cheng K; Zhang Y
    Front Genet; 2023; 14():1107625. PubMed ID: 37051591
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased expression of GGN promotes tumorigenesis in bladder cancer and is correlated with poor prognosis.
    Wang W; Li C; Chen Y; Teng L; Cao Y; Xu Y; Pan H; An R
    Gene; 2018 Apr; 652():7-15. PubMed ID: 29412153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma.
    Chen Y; Tian T; Li ZY; Wang CY; Deng R; Deng WY; Yang AK; Chen YF; Li H
    Cell Death Dis; 2019 May; 10(5):356. PubMed ID: 31043585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer.
    Zhou W; Wang Z; Shen N; Pi W; Jiang W; Huang J; Hu Y; Li X; Sun L
    Mol Cell Biochem; 2015 Jan; 398(1-2):11-9. PubMed ID: 25223638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
    Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
    Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
    Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    Chen F; Wang Q; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma.
    Zhang LH; Wang D; Li Z; Wang G; Chen DB; Cheng Q; Hu SH; Zhu JY
    Hepatobiliary Pancreat Dis Int; 2021 Aug; 20(4):337-344. PubMed ID: 32933876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients.
    Ning XH; Qi YY; Wang FX; Li SC; Jia ZK; Yang JJ
    Biomed Res Int; 2020; 2020():7272960. PubMed ID: 33150179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actin-binding protein Anillin promotes the progression of gastric cancer in vitro and in mice.
    Jia H; Yu F; Li B; Gao Z
    J Clin Lab Anal; 2021 Feb; 35(2):e23635. PubMed ID: 33089886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7‑H3 promotes malignant progression of muscle‑invasive bladder cancer.
    Xu ZL; Zhang Y; Wang L; Li F; Man HW; Li PF; Shan BE
    Oncol Rep; 2018 Nov; 40(5):2722-2733. PubMed ID: 30132557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.